TD Asset Management Inc Has $5.92 Million Stock Holdings in Bausch Health Cos Inc. $BHC

TD Asset Management Inc boosted its position in Bausch Health Cos Inc. (NYSE:BHC) by 5.0% during the second quarter, Holdings Channel reports. The institutional investor owned 889,912 shares of the company’s stock after purchasing an additional 42,236 shares during the quarter. TD Asset Management Inc’s holdings in Bausch Health Cos were worth $5,922,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BHC. SBI Securities Co. Ltd. increased its position in shares of Bausch Health Cos by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company’s stock worth $27,000 after purchasing an additional 3,001 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Bausch Health Cos during the 1st quarter worth approximately $27,000. Cary Street Partners Financial LLC acquired a new position in shares of Bausch Health Cos during the 1st quarter worth approximately $27,000. Wealthquest Corp acquired a new position in shares of Bausch Health Cos during the 1st quarter worth approximately $58,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Bausch Health Cos during the 1st quarter worth approximately $68,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Stock Performance

Shares of NYSE BHC opened at $6.06 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. Bausch Health Cos Inc. has a 12 month low of $4.25 and a 12 month high of $9.85. The stock has a 50 day moving average of $6.94 and a 200-day moving average of $6.01. The company has a market capitalization of $2.25 billion, a P/E ratio of 23.29 and a beta of 0.43.

Bausch Health Cos (NYSE:BHC) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). The business had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Insider Buying and Selling

In other news, Director John Paulson acquired 34,721,118 shares of the firm’s stock in a transaction on Thursday, August 14th. The shares were purchased at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the acquisition, the director directly owned 70,755,869 shares in the company, valued at $636,802,821. This represents a 96.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders acquired 37,964,167 shares of company stock valued at $333,757,793. Corporate insiders own 19.97% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on BHC shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a research report on Wednesday, October 8th. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Bausch Health Cos currently has an average rating of “Hold” and a consensus target price of $9.00.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.